As a financial writer, sometimes you get lucky. That proved to be the case when I wrote about Celldex Therapeutics (CLDX) in January of this year - right before the shares spiked on new-found optimism for the company's innovative oncology program. Since then, the company has reported encouraging (albeit confusing) clinical data and bounced around between $4 and $5.50. Although investors should not underestimate the risks to this story, these shares still look like an under-appreciated play on some very difficult-to-treat cancer types.
Please continue here:
Catching Up With Celldex Therapeutics